Delivery of neuropeptides from the periphery to the brain: Studies with enkephalin

ACS Chemical Neuroscience

Volumn 1, Issue 5, 2010, Pages 399-406

  Shechter, Yoram ^a   Heldman, Eli ^b   Sasson, Keren ^a   Bachar, Tzach ^b   Popov, Mary ^b   Fridkin, Matityahu ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Blood brain barrier; Enkephalin; Neuropeptide; Prodrug; Reversible lypophilization; Reversible conjugation

Indexed keywords

9 FLUORENYLMETHOXYCARBONYLLEUCINE ENKEPHALIN; 9 FLUORENYLMETHOXYCARBONYLMETENKEPHALIN; ENKEPHALIN; LEUCINE ENKEPHALIN; METENKEPHALIN; N 3 PROPIOSUCCINIMIDO 4 AMIDO 9 FLUORENYLMETHOXYCARBONYLLEUCINE ENKEPHALIN 3 THIO (11 UNDECANOIC ACID); NEUROPEPTIDE; S,S' DI (3 SUCCINIMIDO N 3 PROPION 4 AMIDO 9 FLUORENYLMETHOXYCARBONYLLEUCINE ENKEPHALIN) DITHIOTHREITOL; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; HUMAN; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SLOW DRUG RELEASE;

BLOOD-BRAIN BARRIER; ENKEPHALIN; NEUROPEPTIDE; PRODRUG; REVERSIBLE-CONJUGATION; REVERSIBLE-LYPOPHILIZATION;

ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; ENKEPHALIN, LEUCINE; ENKEPHALIN, METHIONINE; ENKEPHALINS; INJECTIONS, INTRAPERITONEAL; LIPIDS; MALE; MICE; MICE, INBRED ICR; NEUROPEPTIDES;

MUS;

EID: 77953301712     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn100001j     Document Type: Article

References (24)

1. Hruby, V. J., Kazmierski, W., Kawasaki, A. M., and Matsunaga, T. O. (1991) Synthetic Chemistry and the Design of Peptide-Based Drugs, in Peptide Pharmaceuticals (Ward, D. J., Ed.) Chapter 5, pp 135 - 184, Open University Press, Buckingham, U.K.
2. Knapp, R. J., Davis, T. P., Burks, T. F., and Yamamura, H. I. (1991) In Peptide Pharmaceuticals, ed. (Ward, D. J., Ed.) Chapter 7, pp 210 - 242, Open University Press, Buckingham, U.K.
3. Partridge, W. M. (1991) Peptide Drug Delivery to the Brain, Raven Press, New York.
4. Witt, K. A., Gillespie, T. J., Huber, J. D., Egleton, R. D., and Davis, T. P. (2001) peptide drug modifications to enhance bioavailablility and blood-brain-barrier permeability Peptides 22, 2329-2343
5. Partridge, W. M. (2005) The blood-brain barrier: bottleneck in brain development J. Am. Soc. Exp. Neuro Ther. 2, 3-14
6. Gershonov, E., Shechter, Y., and Fridkin, M. (1999) Spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin Diabetes 48, 1437-1442
7. 3-insulin J. Med. Chem. 43, 2530-2537
8. Shechter, Y., Goldwaser, I., lavon, I., Gershonov, E., Mester, B., Mironchik, M., Patt, L., and Fridkin, M. (2001) A new approach for prolonging the half-life of peptide, proteins and low-molecular-weight drugs in vivo Drugs Future 26, 669-676
9. 7 interferon-2 Proc. Natl. Acad. Sci. U.S.A. 98, 1212-1217
10. 1 is a long acting prodrug derivative J. Med. Chem. 45, 4264-4270
11. Tsubery, H., Mironchik, M., Fridkin, M., and Shechter, Y. (2004) Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification J. Biol. Chem. 279, 38118-38124
12. 3-36 prolongs its inhibition of food intake in mice FEBS Lett. 579, 2439-2444
13. Shechter, Y., Mironchik, M., Saul, A., Gershonov, E., Sasson, K., Tsubery, H., and Fridkin, M. (2007) New technologies to prolong life-time of peptide and protein drugs in vivo (a review) Int. J. Peptide Res. Ther. 13, 105-117
14. Shechter, Y., Mironchik, M., Rubinraut, S., Saul, A., Tsubery, H., and Fridkin, M. (2005) Albumin-insulin conjugate releasing insulin slowly under physiological conditions; A new concept for long-acting insulin Bioconjugate Chem. 16, 913-920
15. Banks, W. A. and Kastin, A. J. (1990) Peptide transport systems for opiates across the blood-brain barrier Am. J. Physiol. 159, E1-E10
16. Egleton, R. D., Mitchell, S. A., Huber, J. D., Tanders, J., Strropova, D., Polt, R., Yamamura, H. I., Hurby, v.J., and Davis, T. P. (2000) Improved bioavailability to the brain of glycosylated met-enkephalin analogs Brain Res. 881, 37-46
17. D'Amour, F. E. and Smith, D. L. (1941) A method for determining loss of pain sensation J. Pharmacol. Exp. Ther. 72, 74-79
18. Gupta, S., Pasha, S., Gupta, Y. K., and Bardway, D. K. (1999) Chimeric peptide of met-enkephalin and FMRFa induces antinociception and attenuates development of tolerance to morphine antinociception Peptides 20, 471-478
19. Gupta, S., Pasha, S., Gupta, Y. K., and Bardway, D. K. (2001) Effects of intracerebro-ventricularly administered chimeric peptide of met-enkephalin and FMRFa-[D-Ala2]YFa-on antinociception and its modulation in mice Brain Res. Bull. 55, 51-57
20. Polt, R., Porreca, F., Szabo, L. Z., Bilsky, E. J., Davis, P., Abbruscato, T. J., Davis, T. P., Horvath, R., Yamamura, H. I., and Hruby, V. J. (1994) Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier Proc. Natl. Acad. Sci. U.S.A. 91, 7114-7118
21. Fuerteges, F. and Abuchowski, A. (1990) The clinical efficacy of poly(ethyleneglycol) modified proteins J. Controlled Release 11, 139-148
22. Delegado, C., Francis, G. E., and Derek, F. F. (1992) The uses and properties of PEG-linked proteins Crit. Rev. Ther. Drug Carrier Syst. 9, 249-304
23. Reddy, K. R. (2000) Controlled-release, pegylation liposomal formulations: new mechanisms in the delivery of injectable drugs Ann. Pharmacother. 34, 915-923
24. Weber, S. J., Greene, D. L., Sharma, D. D., Yamamura, H. I., Kramer, T. H., Burks, T. F., Hruby, V. J., Hersh, L. B., and Davis, T. P. (1991) Distribution and analgesia of [3H][D-Pen2, D-Pen5]enkephalin and two halogenated analogs after intravenous administration J. Pharmacol. Exp. Ther. 259, 1109-1117